Introduction: The Lipoprotein(a) and Coronary Calcium Conundrum
In the evolving landscape of preventive cardiology, Lipoprotein(a) [Lp(a)] has emerged as a critical, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Unlike low-density lipoprotein cholesterol (LDL-C), Lp(a) levels are largely resistant to traditional lifestyle interventions and standard statin therapy. However, a significant clinical dilemma has persisted: since Lp(a) is known to promote noncalcified plaque formation through its pro-inflammatory and pro-thrombotic properties, is the traditional Coronary Artery Calcium (CAC) score still a reliable tool for these specific patients?
Clinicians have long debated whether a CAC score of zero in an individual with high Lp(a) truly signifies low risk, or if the test simply fails to capture the high-risk noncalcified burden associated with this particle. A recent landmark multicohort study, published in the Journal of the American College of Cardiology, provides much-needed clarity on this interaction, evaluating over 11,000 participants to define the prognostic value of CAC across the spectrum of Lp(a) levels.
Highlights of the Multicohort Study
The study offers several key insights for the modern clinician:
- Lp(a) >50 mg/dL and CAC >0 are independent and additive predictors of ASCVD risk.
- The ‘Power of Zero’ remains relevant: individuals with a CAC of 0 have low absolute event rates, even if their Lp(a) is significantly elevated.
- The combination of high CAC (≥300) and high Lp(a) (>50 mg/dL) identifies a very high-risk phenotype with a six-fold increase in risk compared to those with low levels of both.
- CAC scoring remains one of the most powerful tools for risk stratification in patients with elevated Lp(a), aiding in the decision-making process for intensive preventive therapies.
Study Design and Methodology
To investigate this relationship, researchers utilized a pooled cohort consisting of 11,319 participants drawn from four major U.S.-based prospective studies (including cohorts similar to MESA and CARDIA). All participants were free of known ASCVD at baseline. The primary objective was to evaluate the association between elevated Lp(a) (defined as >50 mg/dL or approximately 125 nmol/L) and incident ASCVD events—including myocardial infarction, stroke, and coronary revascularization—across different strata of CAC scores (0, 1–99, 100–299, and ≥300).
The study population was diverse, with a mean age of 56 years and a slight majority of women (54%). Over a mean follow-up period of 14.8 years, the researchers documented 1,569 incident ASCVD events, providing robust statistical power to detect interactions between these two biomarkers.
Key Findings: Independence and Additivity
The Independent Impact of Lp(a) and CAC
The analysis revealed that both elevated Lp(a) and the presence of coronary calcium are potent, independent drivers of risk. Elevated Lp(a) (>50 mg/dL) was associated with a 24% increase in ASCVD risk (HR: 1.24; 95% CI: 1.09-1.41). Meanwhile, the presence of any calcium (CAC >0) was associated with a much larger hazard ratio of 2.44 (95% CI: 2.14-2.77). Importantly, there was no significant statistical interaction between the two (P-interaction = 0.80), suggesting that the risk conferred by one does not depend on the level of the other; rather, they are cumulative.
The ‘Power of Zero’ in the Context of High Lp(a)
One of the most clinically relevant findings concerns the subgroup of patients with a CAC score of 0. Among these individuals, those with elevated Lp(a) did show a higher relative risk compared to those with low Lp(a) (4.9 vs 3.8 events per 1,000 person-years). However, the absolute event rate remained notably low. This suggests that while high Lp(a) does increase risk even in the absence of calcification, a CAC of 0 still identifies a patient at low short-to-medium-term risk, potentially allowing for the deferral of more aggressive or invasive interventions in primary prevention.
The High-Risk Phenotype: CAC ≥300 and Lp(a) >50 mg/dL
At the other end of the spectrum, the study highlighted a particularly vulnerable group. Individuals with both a CAC score ≥300 and Lp(a) >50 mg/dL faced a staggering 6.12-fold increase in ASCVD risk compared to the reference group (CAC=0 and Lp(a) ≤50 mg/dL). For these patients, the absolute incidence rate of events was significantly higher (21.2 per 1,000 person-years), underscoring the need for aggressive risk factor modification, including intensive lipid-lowering and blood pressure control.
Expert Commentary and Clinical Implications
The biological plausibility of these findings lies in the dual nature of Lp(a). Lp(a) contains an LDL-like particle and a unique protein called apolipoprotein(a). This structure allows it to contribute to the cholesterol pool within the arterial wall (atherogenesis) while also interfering with fibrinolysis (thrombogenesis) and promoting vascular calcification. Historically, some hypothesized that Lp(a) might lead to ‘soft’ plaques that would be invisible to CT scans. This study debunks the idea that CAC is irrelevant in these patients; instead, it shows that calcification remains a reliable surrogate for the total atherosclerotic burden, even when driven by Lp(a).
From a health policy and guideline perspective, these results support the selective use of CAC scoring to refine risk in patients found to have high Lp(a). For a patient in the ‘intermediate risk’ category with high Lp(a), a CAC score can serve as a tie-breaker. A score of 0 might support a more conservative approach, whereas any positive score should likely trigger a transition to high-intensity preventive care.
Conclusion
This multicohort study provides definitive evidence that CAC scoring is not rendered obsolete by the presence of elevated Lipoprotein(a). While Lp(a) is a dangerous independent risk factor, CAC remains a superior predictor of absolute clinical events. In the clinical setting, combining these two markers allows for a more nuanced and individualized approach to cardiovascular prevention. As we await the results of ongoing clinical trials for specific Lp(a)-lowering therapies, such as antisense oligonucleotides and siRNA molecules, the CAC score remains our most reliable ‘crystal ball’ for determining which patients with high Lp(a) require the most vigilant protection.
References
1. Bhatia HS, Fan Y, Dharmavaram G, et al. Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study. Journal of the American College of Cardiology. 2026; (41837904).
2. Tsimikas S. Lipoprotein(a) as a Cardiovascular Risk Factor: Current Status. Current Opinion in Lipidology. 2022;33(1):35-44.
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285-e350.
